Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures.
JC virus (JCV) is a polyomavirus that infects human oligodendrocytes, leading to development of progressive multifocal leukoencephalopathy (PML), an often fatal demyelinating disease occurring in immunocompromised individuals. Currently there are no effective therapies for the treatment of PML that result in clearance of JCV from the brain. Cidofovir (CDV) is an acyclic nucleoside phosphonate that inhibits DNA polymerases and has been used for the treatment of PML. However, CDV demonstrated little efficacy as a treatment for PML and causes substantial side effects to patients. To improve efficacy and reduce the toxicity of CDV, a lipid-ester derivative, CMX001, was generated by Chimerix and is currently in multicenter phase II clinical trials for the prevention or control of cytomegalovirus infection in hematopoietic stem cell transplant recipients and of BK virus in the urine of stem cell or renal allograft recipients. CMX001 caused minimal cytotoxic effects in human fetal brain SVG cells when used at concentrations between 0.01 μM and 0.1 μM. CMX001 resulted in a dose-dependent decrease in the number of JCV-infected cells during initial infection and nearly eliminated JCV-infected cells during an established infection. In addition, CMX001 treatment resulted in a 60% reduction in JCV DNA copy number during initial infection, which suggests that suppression of JCV infection by CMX001 is likely due to inhibition of virus DNA replication. This study demonstrates that CMX001 suppresses JCV infection at concentrations that have limited toxicity to human brain cells, indicating its potential use to limit JCV replication in infected patients.
Jiang
Zhi-Gang
ZG
Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke/NIH, 10 Center Drive, Bethesda, MD 20892-1296, USA.
Cohen
Jeffrey
J
Marshall
Leslie J
LJ
Major
Eugene O
EO
D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D001921:Brain / Q000166:cytology* / Q000196:embryology*; D002460:Cell Line; D003596:Cytosine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D005333:Fetus / Q000166:cytology*; D006801:Humans; D017403:In Situ Hybridization; D007577:JC Virus / Q000187:drug effects*; D008858:Microscopy, Phase-Contrast; D015394:Molecular Structure; D063065:Organophosphonates / Q000737:chemistry / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D063065:Organophosphonates; C525733:brincidofovir; D003596:Cytosine
J Virol Methods. 2004 Nov;121(2):217-21
15381359
Trends Biotechnol. 2004 Aug;22(8):423-7
15283988
Oncol Res. 1998;10(10):523-31
10338155
Drugs. 1999 Aug;58(2):325-45
10473024
J Virol. 1991 Feb;65(2):1002-6
1846179
Proc Natl Acad Sci U S A. 1985 Feb;82(4):1257-61
2983332
Proc Natl Acad Sci U S A. 1986 Sep;83(17):6347-51
3018726
Drugs. 2009;69(2):151-66
19228073
Annu Rev Med. 2010;61:35-47
19719397
J Infect Dis. 2007 Sep 1;196(5):712-8
17674314
AIDS. 1989 Dec;3(12):843-5
2561055
J Neurovirol. 2001 Aug;7(4):375-81
11517420
AIDS. 2008 Sep 12;22(14):1759-67
18753934
Infection. 2007 Feb;35(1):33-6
17297588
J Virol. 1996 Oct;70(10):7004-12
8794345
Ann Neurol. 2003 May;53(5):636-46
12730998
Antimicrob Agents Chemother. 2006 Apr;50(4):1564-6
16569886
Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):460-3
12750243
Antimicrob Agents Chemother. 2004 Feb;48(2):404-12
14742188
J Neurovirol. 1998 Feb;4(1):59-68
9531012
Mol Pharmacol. 1996 Dec;50(6):1502-10
8967971
Biochim Biophys Acta. 1988 Dec 20;951(2-3):382-7
2905172
Am J Pediatr Hematol Oncol. 1989 Spring;11(1):74-86
2496615
Antimicrob Agents Chemother. 1997 Mar;41(3):587-93
9055998
J Virol. 1998 Dec;72(12):9918-23
9811728
Antimicrob Agents Chemother. 2009 May;53(5):1840-9
19258267
Ann Pharmacother. 2001 Jun;35(6):741-4
11408993
Lancet Neurol. 2010 Apr;9(4):438-46
20298967
Antiviral Res. 2009 May;82(2):A84-98
19425198
Proc Natl Acad Sci U S A. 1990 Nov;87(22):8692-6
2174160
N Engl J Med. 1998 May 7;338(19):1345-51
9571254
Rheumatology (Oxford). 2007 May;46(5):888-90
17389659
Prog Med Virol. 1989;36:42-61
2555837
J Virol. 2004 May;78(9):4884-91
15078969
J Neurovirol. 1998 Aug;4(4):451-6
9718138
Curr Opin Neurol. 1995 Jun;8(3):184-90
7551117
J Neuroimmune Pharmacol. 2010 Sep;5(3):404-17
20401541
Acta Neurol Scand. 1994 Dec;90(6):443-7
7892765
Intervirology. 2007;50(6):412-7
18182774
Eur J Intern Med. 2009 May;20(3):261-7
19393493